Filing Flows › Comparisons › KYNB vs AKTS
Kyntra Bio vs Aktis Oncology: KYNB and AKTS compared
Kyntra Bio is the larger company: $3.7M of revenue in its latest quarter (Q1 2026) against $3.4M for Aktis Oncology (Q2 2026). Aktis Oncology is growing faster (+111% against +36% a year earlier). Kyntra Bio is more profitable, with an operating margin of -369.7% against -854.0%.
Where the money goes: KYNB and AKTS
Kyntra Bio (KYNB) · Q1 2026
Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%, net loss $15.2M, operating cash flow −$13.9M. The chart follows the revenue to costs, profit and cash.
Aktis Oncology (AKTS) · Q2 2026
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart follows the revenue to costs, profit and cash.
| Kyntra Bio (KYNB) | Aktis Oncology (AKTS) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $3.7M | $3.4M |
| Revenue growth, Y/Y | +36% | +111% |
| Operating margin | -369.7% | -854.0% |
| Net earnings | −$15.2M | −$24.1M |
| Net margin | -406.6% | -713.5% |
| Operating cash flow | −$13.9M | −$20.6M |
Where the revenue comes from
Kyntra Bio
- Drug Product Revenue: $3.5M (93%)
- Development and Other Revenue: $246K (7%)
Questions
Which is bigger, Kyntra Bio or Aktis Oncology?
Kyntra Bio is the larger company: $3.7M of revenue in its latest quarter (Q1 2026) against $3.4M for Aktis Oncology (Q2 2026).
Is Kyntra Bio or Aktis Oncology growing faster?
Aktis Oncology is growing faster (+111% against +36% a year earlier).
Which is more profitable, Kyntra Bio or Aktis Oncology?
Kyntra Bio is more profitable, with an operating margin of -369.7% against -854.0%.
More: Kyntra Bio earnings · how Kyntra Bio makes money · Aktis Oncology earnings · how Aktis Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 12, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.